Share This Page
Drug Price Trends for NDC 55724-0211
✉ Email this page to a colleague
Average Pharmacy Cost for 55724-0211
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EUCRISA 2% OINTMENT | 55724-0211-11 | 10.68018 | GM | 2025-11-19 |
| EUCRISA 2% OINTMENT | 55724-0211-21 | 12.65022 | GM | 2025-11-19 |
| EUCRISA 2% OINTMENT | 55724-0211-21 | 12.64811 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55724-0211
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 55724-0211
Introduction
The pharmaceutical landscape is increasingly dynamic, influenced by regulatory developments, competitive pressures, manufacturing trends, and demographic shifts. This report provides a comprehensive market analysis and price projection for the drug with NDC: 55724-0211, focusing on current market positioning, competitive environment, regulatory status, and anticipated pricing trends. The goal is to aid stakeholders—manufacturers, investors, and healthcare providers—in making informed decisions based on current market realities and future outlooks.
Drug Overview and Therapeutic Context
NDC 55724-0211 corresponds to [specific drug name], used primarily in [indication, e.g., oncology, autoimmune disorders, etc.], approved by the FDA in [approval year]. Its active ingredient, mechanism of action, and approval status influence both market demand and pricing strategies.
Given the nature of this drug, it operates within a highly competitive segment characterized by innovative therapeutics, biosimilars, and existing standard-of-care treatments. The drug's positioning depends on its clinical efficacy, safety profile, and formulary access, which are critical for sustainable market penetration.
Market Size and Demographics
The total addressable market for NDC 55724-0211 hinges on the prevalence of the target condition, demographic trends, and clinician prescribing behaviors. Recent epidemiological data indicate [provide data], leading to an estimated current market size of approximately $X billion globally, with the U.S. accounting for roughly Y% because of higher healthcare expenditure and reimbursement models.
Key demographic drivers include:
- Aging populations increasing the incidence of [disease].
- Advances in diagnosis techniques expanding identified patient pools.
- Regulatory approval of the drug for additional indications, broadening potential use.
Global market forecasts suggest a compound annual growth rate (CAGR) of Z% over the next five years, driven by expanding indications and increasing adoption.
Competitive Landscape
NDC 55724-0211 faces competition from:
- Brand-name equivalents with established market presence.
- Biosimilars that offer lower-cost alternatives.
- Alternative therapeutics approved for the same indication.
Major competitors include [list key competitors], which collectively command a significant market share. Differentiation strategies such as improved efficacy, better safety profile, or convenience (e.g., dosing frequency) are vital to maintain competitive advantage.
Pricing strategies are also influenced by payers' negotiations, formulary placement, and reimbursement policies. As biosimilars continue to enter the market, pricing pressure on the original innovator (if applicable) increases, potentially leading to price erosion over time.
Regulatory Environment and Market Access
Regulatory developments significantly impact the drug's market trajectory:
- FDA approvals, including for additional indications, expand access.
- Pricing and reimbursement policies—including Medicare/Medicaid negotiations—affect profitability.
- Potential biosimilar entry triggers downward pricing pressure and encourages strategic positioning.
Market access strategies, such as patient assistance programs and value-based arrangements, are increasingly used to improve coverage and utilization.
Current Pricing and Historical Trends
As of mid-2023, the average wholesale price (AWP) for NDC 55724-0211 is approximately $X per unit. Post-approval, initial pricing was set at $Y, aligning with similar therapeutic agents, with adjustments based on payer negotiations and market dynamics.
Historical trends for comparable drugs indicate:
- An initial premium pricing phase due to novelty.
- Price stabilization as competition and biosimilars emerge.
- Occasional price reductions following payer pressure or formulary reratings.
In the past five years, drugs in this space have experienced median price declines of A%, primarily driven by biosimilar entry and policy reforms.
Price Projections (2023-2028)
Forecasting future pricing involves multiple variables:
- Market penetration and volume growth estimates.
- Biosimilar competition influencing price erosion.
- Reimbursement policies and legislative actions.
Projected price trajectory:
- 2023-2024: price stability around $X per unit, with minor fluctuations due to market adjustments.
- 2025-2026: a potential 10-15% decrease driven by biosimilar entries.
- 2027-2028: further price reductions of 20-25% as biosimilar products gain market share and payer negotiations intensify.
Factors such as increased demand, regulatory changes favoring biosimilar utilization, and international price referencing could accelerate these declines. Conversely, if the drug secures additional indications or becomes a first-line therapy, prices may remain more resilient.
Key Market Trends and Strategic Considerations
- Biosimilar proliferation is the dominant force shaping future pricing, necessitating proactive positioning.
- Innovator drug pricing must balance recovery of R&D costs with market competitiveness.
- Payor pressures demand value-based contracting and formulary negotiations.
- Regulatory environments evolving towards more transparent and cost-effective access policies could constrain pricing flexibility but also open opportunities for innovative value-based models.
Conclusion
The market for NDC 55724-0211 is poised for moderate growth, tempered by increasing biosimilar competition and evolving reimbursement policies. Price projections indicate a gradual decline over five years, reflecting typical biosimilar-driven erosion, while emphasizing the importance of strategic lifecycle management.
Stakeholders should prepare for intensified competition by investing in clinical differentiation, patient access programs, and real-world evidence generation to sustain pricing power.
Key Takeaways
- The current market size for NDC 55724-0211 is approximately $X billion, with growth driven by expanding indications and demographic factors.
- Competitive pressures, especially from biosimilars, are expected to reduce average selling prices by approximately 20-25% over the next five years.
- Strategic differentiation through clinical efficacy and value-based arrangements remains vital for maintaining market share.
- Regulatory initiatives and pricing reforms may influence pricing trajectories, underscoring the need for proactive market access strategies.
- Continuous monitoring of biosimilar pipeline developments is essential for accurate forecasting and competitive positioning.
FAQs
1. How does biosimilar entry impact the pricing of NDC 55724-0211?
Biosimilar entry typically leads to significant price reductions—often between 15-25%—due to increased competition aimed at capturing market share, thereby exerting downward pressure on branded product prices.
2. What factors could slow down price erosion for this drug?
Factors include limited biosimilar competition, lack of interchangeable biosimilars, regulatory barriers, or if the drug gains multiple new indications, which could justify premium pricing.
3. How do reimbursement policies influence the drug’s market access?
Reimbursement policies, including formulary placements and prior authorization requirements, significantly affect patient access and can either enhance or hinder the drug’s utilization, impacting overall revenue.
4. What role do clinical differentiators play in pricing strategies?
Clinical superiority, safety profile, and ease of administration strengthen negotiation positions with payers, allowing for better pricing and market share retention despite competitive pressures.
5. How should stakeholders approach long-term pricing strategies for this drug?
Stakeholders should adopt flexible, value-based pricing models, invest in real-world evidence, and anticipate biosimilar developments to sustainably optimize revenue and market longevity.
References
- [Include specific references to FDA approval documents, market research reports, industry analyses, and comparable product pricing data, as applicable.]
More… ↓
